Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.

THE NovoTTF-100L SYSTEM IS NOW FDA approved to treat mesothelioma*

*Unresectable, locally advanced or metastatic, malignant pleural mesothelioma.

Learn more
SCROLL

PUT GBM ON PAUSE

PUT LIFE ON PLAY

Josh is JB’s brother
and caregiver.
JB is an
Optune user.

THE NovoTTF-100L SYSTEM IS NOW FDA approved to treat mesothelioma*

*Unresectable, locally advanced or metastatic, malignant pleural mesothelioma.

Learn more

OPTUNE + TMZ HAS BEEN PROVEN TO

PROVIDE LONG-TERM QUALITY SURVIVAL

TO PATIENTS WITH NEWLY DIAGNOSED GBM1,2

Patient-reported data collected per EORTC QLQ-C30 at baseline and Months 3, 6, 9, and 12. The 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).

Quality of life study

The updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers now include alternating electric field therapy (Optune) in combination with temozolomide (TMZ) following maximal safe resection and standard brain radiation therapy with concurrent TMZ as Category 1 recommended treatment option for patients with newly diagnosed supratentorial glioblastoma (GBM) and good performance status.* There is uniform NCCN consensus for this recommendation based on high-level evidence (Category 1).

JB is an Optune user JB is an Optune user

"I was initially concerned because I didn't fully understand what it would be like. But, I overcame my fears ... [and] in a matter of weeks, I was at ease toting the backpack."

-JB, Optune user

"I was initially concerned

because I didn't fully understand what

it would be like. But, I overcame my

fears ... [and] in a matter of weeks,

I was at ease toting the backpack."

-JB, Optune user
Maintained Quality of Life

Maintained quality of life and daily functioning with Optune2

Optune Device Optune Device

Find out more about Optune
and how to start patients on therapy

*The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial for which the IFU is based used an eligibility criteria of KPS ≥70.

The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Daily-functioning domains evaluated were Physical, Role, Social, Emotional, and Cognitive as determined by the EORTC QLQ-C30 core questionnaire.

References: 1. Optune Instructions for Use. Novocure 2019. 2. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with Tumor-Treating Fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495–504. doi: 10.1001/jamaoncol.2017.5082. 3. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467-473. https://doi.org/10.1007/s11060-018-03057-z. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. V.1.2018. © 2018 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed March 20, 2018. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).